

TO: FDA Advisory Committee

This is to let the Advisory Committee know that without the drug Oxycontin I am virtually a invalid. Oxycontin is not a dangerous drug - I have been taking it for years with no adverse side effects.

Just because someone doesn't take the drug as prescribed is no reason to make us pain patients suffer and that is what you will be doing if you take Oxycontin off the market.

Please leave the prescription drug Oxycontin on the market

Doug Mason
Rt 3 Box 3307
Trinity, TX
75862



Purdue Pharma L.P.

One Stamford Forum
Stamford, CT 06901-3431
(203) 588 8000
Fax (203) 588 8850
www.purduepharma.com

Meeting has been
postponed for
September 13-14

May 11, 2001

Dear Clinician:

The attached *Federal Register* notice announces an Advisory Panel Meeting of the FDA to discuss the use of opioid analgesics for the treatment of chronic non-cancer pain and pain in the pediatric population. During the meeting, the panel will discuss the risk versus benefits of using opioid analgesics for the treatment of pain. The meeting will be held in Gaithersburg, Maryland on June 14 and 15, 2001, from 8:00 a.m. to 5:00 p.m.

Since you have expressed an interest in supporting appropriate and effective pain management, you may be interested in either attending or providing comments for this meeting. You may also want to purchase a video tape of the meeting, or listen to the meeting on a live television feed or telephone line. Details are included in the attachment. If you're interested in one of these options, please contact Kimberly Topper at the FDA **no later than June 7**. Please feel free to share this information with any of your colleagues who may be interested.

The debate on the use of opioids for nonmalignant pain could have a profound impact on the future of pain management in the U.S. By working together, we can ensure that the voices of millions of pain patients are heard in this debate.

Sincerely,

Robert F. Reder, MD
Vice President, Medical Affairs and Worldwide Drug Safety

attachment

The following information is from the *Federal Register*, May 3, 2001 (Volume 66, Number 86):

TITLE: Anesthetic and Life Support Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration

ACTION: Notice

Name of Committee: Anesthetic and Life Support Drugs Advisory Committee

Date and Time: The meeting will be held on June 14 and 15, 2001, 8 a.m. to 5 p.m.

Location: Holiday Inn, The Ballroom, Two Montgomery Village Ave., Gaithersburg, MD

Contact:

Kimberly Topper
Center for Drug Evaluation and Research (HFD-21)
Food and Drug Administration
5600 Fishers Lane
Rockville MD 20857
301-827-7001, fax 301-827-6801
e-mail: topperk@cder.fda.gov

Or: FDA Advisory Committee Information Line
1-800-741-8138, code 12529
(301-443-0572 in the Washington, DC area)

Please call the Information Line for up-to-date information on this meeting.

Agenda:

On both days the committee will discuss the medical use of opiate analgesics in various patient populations, including pediatric patients and patients with chronic pain of nonmalignant etiology, as well as the risk to benefit ratio of extending opiate treatment into these populations. It will also address concerns regarding the abuse potential, diversion and increasing incidence of addiction to opiate analgesics, especially to the modified release opiate analgesics.

Procedure:

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

Written submissions may be made to the contact person by June 7, 2001.

Oral presentation from the public will be scheduled between approximately 1 p.m. and 2 p.m. each day. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before June 7, 2001, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Background material from FDA will be posted 24 hours before the meeting at the Anesthetic and Life Support Drugs Advisory Committee docket site at <http://www.fda.gov/ohrms/dockets/ac/acmenu.htm>. (Click on the year 2001 and scroll down to Anesthetic and Life Support Drugs meetings.) This is the same Web site where you can find the minutes, transcript, and slides from the meeting. This material is generally posted about 3 weeks after the meeting.